Wondering if Vertex Pharmaceuticals at around US$470 a share is offering fair value, or if you are paying up for quality, you ...

The market expects Vertex Pharmaceuticals (VRTX) to deliver a year-over-year increase in earnings on higher revenues when it ...

Novo takes aim at Hims & Hers over compounded version of Wegovy pill; The flaw with TrumpRx; Vertex Pharmaceuticals’ CRISPR ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is among the most profitable healthcare stocks to buy. On January 26, UBS ...

The biotech could be on the verge of expanding its lineup and entering a new era of growth.

China-based biologics CDMO WuXi Biologics (HKEX: 2269) has signed a license and research services agreement with US biotech Vertex Pharmaceuticals (Nasdaq: VRTX) covering a preclinical trispecific ...

Investors with a lot of money to spend have taken a bearish stance on Vertex Pharmaceuticals (NASDAQ:VRTX). And retail traders should know. We noticed this today when the positions showed up on ...

Vertex Pharmaceuticals (VRTX) has been in focus after a series of analyst upgrades related to its cystic fibrosis franchise ...

Vertex Pharmaceuticals dominates the cystic fibrosis treatment market and recently has expanded into other therapeutic areas. The biotech predicts full-year 2025 revenue of as much as $12 billion.

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $508.25, a high estimate of $564.00, and a low estimate of $414.00. This current ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is the leading drugmaker in the treatment of cystic fibrosis, a life-threatening genetic disease that causes infections to several organs, including the lungs and ...